Introduction {#sec1}
============

Tobacco use continues to be the leading cause of preventable deaths in the United States as well as globally. Current statistics reveal that smoking-related diseases are responsible for nearly 6 million premature deaths globally annually.^[@ref1]^ In the United States, tobacco use is responsible for nearly 1 in 5 deaths that is approximately 443 000 premature deaths.^[@ref2]^ In 2010, an estimated 23% (58.3 million) of U.S. adults were current cigarette smokers.^[@ref3]^ Tobacco use increases the risk of multiple cancers such as cancers of the lung, mouth, nasal cavities, larynx, pharynx, esophagus, stomach, colorectum, liver, pancreas, kidney, bladder, uterine, cervix, ovary, and myeloid cells. Therefore, smoking accounts for at least 30% of all cancer deaths and 87% of lung cancer deaths.^[@ref4]^

Due to the well-documented negative heath consequences, approximately 70% of smokers want to quit and about 40% try to quit every year. Of those who try to quit, only about 7% stay off nicotine for more than a year. The vast majority do not make it even a week without cigarettes. The major factor that is attributed to the initiation and sustaining of smoking is the presence of nicotine (**1**), the addictive substance in tobacco. Nicotine can produce a myriad of behavioral effects and is unquestionably one of the most popular and powerful reinforcing agents. Both the psychological and physiological effects of tobacco smoke are a result of nicotine's activation of various nicotinic acetylcholine receptor (nAChR) subtypes. For example, nicotine interacts with α4β2-, α4β2α6\*-, α4β2α5\*, and α7-nAChR in the dopaminergic mesolimbic pathway, a brain system thought to mediate the pleasurable and rewarding effects of most substances of abuse, including nicotine.^[@ref5]^ In addition, currently, the few treatments for nicotine dependence include nicotine replacement therapies (NRT); the antidepressant buproprion^[@ref6],[@ref7]^ (**2**), which acts as a dopamine uptake inhibitor in addition to its properties as a nicotinic antagonist of α3β4- and α4β2-nAChRs;^[@ref8]^ and the FDA-approved varenicline^[@ref9],[@ref10]^ (**3**), which acts as a partial nicotine agonist at the α4β2 and a full agonist at the α3β4- and α7*-*nAChRs.^[@ref11]^ In addition, varenicline has affinity for α6β2\*-nAChR equal to that at α4β2-nAChR, but functionally varenicline was more potent in stimulating α6β2\* versus α4β2\* mediated \[^3^H\]dopamine release from rat striatal synaptosomes.^[@ref12]^ However, side effects such as gastrointestinal disturbances (nausea and vomiting) and neuropsychiatric effects (trouble sleeping, unusual dreams, violent or suicidal ideation) were frequently reported with the use of varenicline. In addition, recent evidence suggests that varenicline produces increased risk of heart attack, stroke, and/or other cardiovascular problems.^[@ref13]^ Therefore, there is need for development of new and improved pharmacotherapies for smoking cessation.

The natural alkaloid epibatidine (**4**, *exo*-2-(2′-chloro-5′-pyridinyl)-7-azabicyclo\[2.2.1\]heptane) is an important lead structure in the development of pharmacotherapies for treating nicotine addiction as well as other central nervous system (CNS) disorders including Alzheimers and Parkinson's diseases, pain, schizophrenia, anxiety, depression, and Tourette's syndrome among others.^[@ref14]^ Since its isolation and structural determination in 1992,^[@ref15]^ epibatidine has drawn a lot of interest because of its very high affinity for the α4β2\*-nAChRs.^[@ref16],[@ref17]^ In previous studies, we reported the synthesis, nAChR binding affinity, and pharmacological properties of a number of epibatidine analogues.^[@ref18],[@ref19]^ Interestingly, some analogues retained high affinity for nAChR but unlike epibatidine showed no agonist activity in the acute mouse antinociception test and were antagonists of nicotine-induced antinociception in these assays.^[@ref18]−[@ref20]^ For example, we identified 2′-fluoro-3′-(4-nitrophenyl)deschloroepibatidine (**5a**), also referred to as RTI-7527-102 and 4-nitro-PFEB, as an nAChR ligand with a *K*~i~ value of 0.009 nM for inhibition of \[^3^H\]epibatidine binding. This compound also showed potent antagonism of nicotine-induced antinociception in the tail-flick and hot-plate tests in mice.^[@ref21]^ In a separate study, we showed that **5a** was a competitive antagonist of human α4β2-nAChRs with a potency 17-fold higher than that of dihydro-β-erythroidine (**6**) with very low efficacy at α3β4- and α7-nAChRs.^[@ref22]^ In a more recent study, the α4β2-nAChR antagonist **5a** attenuated the discriminative stimulus effects of nicotine, reduced nicotine's ability to facilitate intracranial self-stimulation (ICSS), blocked conditioned place preference (CPP) produced by nicotine in mice, and dose-dependently blocked nicotine self-administration in rats.^[@ref23]^ Thus, **5a** has both in vitro and in vivo properties thought to be favorable for a potential pharmacotherapy to treat smokers. However, the presence of a nitro-substituted phenyl group, a system that is associated with toxicity via partial reduction in vivo to the hydroxylamine, which can undergo metabolic activation to an electrophilic nitroso species of **5a**, raises concern about its future development. In a recent study, we reported that replacement of the 4-nitro group in **5a** by other strong electron-withdrawing groups led to compounds **5b**--**g** that retained high affinity for α4β2-nAChRs and potent antagonist activity in the tail-flick test.^[@ref24]^

In this study, we report the synthesis, nAChR binding, and pharmacological properties of compounds **7a**--**e** and **8a**--**e**. Compound **7a** is a bioisosteric analogue of **5a** where the nitrophenyl group has been replaced by a pyridine nitrogen. Compound **8a** is a similar bioisosteric analogue of **5g**, a compound that has a *K*~i~ value of 0.053 nM of affinity for inhibition of \[^3^H\]epibatidine binding and AD~50~ values of 0.5 and 130 μg/kg in the tail-flick and hot-plate tests.^[@ref24]^ The syntheses and evaluation of analogues **7b**--**e** and **8b**--**e** allowed a determination of the effects of electron-withdrawing and -donating groups on the pyridine ring. See Chart [1](#cht){ref-type="chart"} for the structures of the compounds described in the above paragraphs.

![Structures of Compounds **1**--**4**, **5a**--**g**, **6**, **7a**--**e**, and **8a**--**e**](jm-2013-01602p_0002){#cht}

Chemistry {#sec1.1}
---------

The synthetic route to the **7a**--**c** and **8a**--**e** analogues commenced with the intermediate 7-*tert*-butoxycarbonyl-2-*exo*-(2′-amino-3′-bromo-5′-pyridinyl)-7-azabicyclo\[2.2.1\]heptane (**9**) prepared in several steps from *N*-Boc pyrrole as reported in earlier work.^[@ref25],[@ref26]^ As outlined in Scheme [1](#sch1){ref-type="scheme"}, the Suzuki cross-couplings of the haloboronic acids, that is, 2-fluoropyridine-5-boronic acid, 2-fluoropyridine-4-boronic acid, 2-chloropyridine-5-boronic acid, and 2-chloropyridine-4-boronic acid with the 2′-amino-3′-bromo compound **9**, carried out in the presence of palladium diacetate, tri-(*o*-tolyl)phosphine, and sodium carbonate, heated at 80 °C in 1,2-dimethoxyethane and water for 5 h furnished the bipyridine intermediates **11b**, **11c**, **12b**, and **12c**.^[@ref27]^ Suzuki cross-coupling of pyridine-4-boronic acid, pyridine-3-boronic acid, and 2-methoxypyridine-5-boronic acids with **9** in the presence of tetrakis(triphenylphosphine) palladium(0) as the catalyst, potassium carbonate as the base, and toluene (15 mL), ethanol (1.5 mL), and water (1.5 mL) as solvents and heating at reflux for 24 h in a sealed tube provided the cross-coupled products **11a**, **11d**, and **12a** in good yields. Conversion of the amino group to the fluoro group along with a concomitant removal of the *tert*-butyloxycarbonyl protecting group in the intermediates **11a**--**d** and **12a**--**c** performed through the diazotization reaction with sodium nitrite in the presence of hydrogen fluoride in pyridine (70%) furnished the products **8a**--**e** and **7a**--**c**. Compound **8d** was synthesized by subjecting 2-*exo*-(2′-fluoro-3′-bromo-5′-pyridinyl)-7-azabicyclo\[2.2.1\]heptane **10**([@ref21]) to a Suzuki--Miyaura cross-coupling with 2-aminopyridine-5-pinacol boronic ester in the presence of tetrakis(triphenylphosphine) palladium(0), potassium carbonate, 1,4-dioxane, and water, heated at 110 °C in a sealed tube overnight. The reaction furnished the diamine **8d** in a 67% yield (Scheme [1](#sch1){ref-type="scheme"}).
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The synthesis of the 2-*exo-*\[2′-fluoro-3′-(2-aminopyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane **7d**, was accomplished in a "one-pot" reaction that combined the borylation and the Suzuki--Miyaura steps (Scheme [2](#sch2){ref-type="scheme"}). The borylation reaction was accomplished using Buchwald's dialkylphosphinobiphenyl ligand, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos), and tris(dibenzylideneacetone)dipalladium (0) as the catalytic system.^[@ref28],[@ref29]^ Cross-coupling of 2-amino-4-bromopryidine (**13**) and bis(pinacolato)diborane in the presence of XPhos, tris(dibenzylideneacetone)dipalladium (0), and potassium acetate heated at 110 °C in 1,4-dioxane converted **13** to the boronic ester, which was carried on to the next step directly by addition of 2′-fluoro-3′-bromo intermediate **10**, tribasic potassium phosphate as base, and an additional 3 mol % of tris(dibenzylideneacetone)dipalladium (0) and heating at 110 °C for 18 h to provide **7d**. Compound **7e** was synthesized as shown in Scheme [3](#sch3){ref-type="scheme"}. Borylation of **14** was achieved by cross-coupling with bis(pinacolato)diborane heated at 80 °C in the presence of 1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride, potassium acetate, and dimethylformamide as the solvent to provide the pinacol boronic ester **15** (Scheme [3](#sch3){ref-type="scheme"}). Compound **15** was cross-coupled with 2′-fluoro-3′-bromo intermediate **10** to furnish 2-*exo-*\[2′-fluoro-3′-(2-methoxypyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**7e**).
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Biology {#sec1.2}
-------

The inhibition of \[^3^H\]epibatidine binding at α4β2\*-nAChRs were conducted as previously reported.^[@ref21]^ The binding assays were performed using tissue homogenates prepared from freshly collected cerebral cortices from adult male Sprague--Dawley rats. These homogenates were frozen at −80 °C until use. It should be noted that, although this brain region contains a variety of nAChRs, α4β2 is the predominant (\>90%) subtype. The epibatidine analogues were tested for agonist and antagonist activity at rat α4β2-, α3β4-, and α7-nAChRs in an in vitro electrophysiology assay as previously described.^[@ref24]^ The epibatidine analogues were tested in mice for their effects on body temperature and two pain models (tail-flick and hot-plate assays) after acute administration as previously described.^[@ref21]^ For the antagonist experiments, male ICR adult mice were pretreated subcutaneously (sc) with either saline or epibatidine analogues 10 min before nicotine. Nicotine was administered at a dose of 2.5 mg/kg, sc (an ED~84~ dose), and mice were tested 5 min later. ED~50~ and AD~50~ values with 95% confidence limits were determined.

Results and Discussion {#sec2}
======================

The nAChR binding affinities and the functional nicotinic pharmacological properties of 2′-fluoro-3′-(substituted pyridine)deschloroepibatidine analogues **7a**--**e** and **8a**--**e** were determined. The *K*~i~ values for the inhibition of \[^3^H\]epibatidine binding at the α4β2\*-nAChRs for compounds **7a**--**e** and **8a**--**e** along with reference compounds nat-epibatidine (**4**), varenicline (**3**), and the lead compounds **5a** and **5g** are listed in Table [1](#tbl1){ref-type="other"}. The reference standards nat-epibatidine and varenicline and lead compounds **5a** and **5g** have *K*~i~ values of 0.026, 0.12, 0.009, and 0.053 nM for the α4β2\*-nAChR, respectively.^[@ref24]^ The pyridine bioisosteres **7a** and **8a** of **5a** and **5b**, respectively, had *K*~i~ values of 0.12 and 0.35 nM, respectively, for α4β2\*-nAChR. Even though **7a** and **8a** have *K*~i~ values slightly less than **5a** and **5g**, respectively, their *K*~i~ values are still subnanomolar and thus have potent affinity for nAChRs labeled by \[^3^H\]epibatidine.

###### Radioligand Binding and Efficacy Profile Data for 2′-Fluoro-3′-(substituted pyridine)deschloroepibatidine Analogues

![](jm-2013-01602p_0006){#fx1}

                                                                              agonist activity at 100 μM (% of max ACh activity)[d](#t1fn4){ref-type="table-fn"}   antagonist activity at 100 μM (% ACh response remaining)[e](#t1fn5){ref-type="table-fn"}                                    
  ------------------------------------------ -------- ------- --------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ----------- -------- ----------- ---------
  nicotine[c](#t1fn3){ref-type="table-fn"}                    1.50 ± 0.30     40 ± 1                                                                               37 ± 3                                                                                     43 ± 5      nd       nd          nd
  nat-epibatidine                                             0.026 ± 0.002   131 ± 13                                                                             97 ± 4                                                                                     150 ± 8     nd       nd          nd
  varenicline                                                 0.12 ± 0.02     13 ± 0.4                                                                             66 ± 4                                                                                     74 ± 5      38 ± 2   nd          nd
  **5a**[f](#t1fn6){ref-type="table-fn"}     NO~2~    H       0.009 ± 0.001   0                                                                                    4 ± 1                                                                                      6 ± 1       6 ± 1    9 ± 2       55 ± 6
  **5g**[f](#t1fn6){ref-type="table-fn"}     H        NO~2~   0.053 ± 0.004   1.0 ± 0.1                                                                            1.3 ± 0.2                                                                                  6 ± 1       5 ± 1    2.1 ± 0.4   17 ± 3
  **7a**                                     H                0.12 ± 0.03     1.5 ± 0.3                                                                            7 ± 1                                                                                      8 ± 2       6 ± 1    34 ± 4      45 ± 4
  **7b**                                     F                0.067 ± 0.01    3 ± 0.3                                                                              5 ± 0.4                                                                                    2 ± 0.5     10 ± 1   27 ± 2      44 ± 4
  **7c**                                     Cl               1.18 ± 0.14     1.2 ± 0.2                                                                            4 ± 0.4                                                                                    3 ± 0.3     7 ± 1    20 ± 1      31 ± 3
  **7d**                                     NH~2~            0.13 ± 0.005    3.9 ± 0.5                                                                            0                                                                                          10 ± 4      8 ± 1    9 ± 1       32 ± 10
  **7e**                                     CH~3~            0.04 ± 0.012    0                                                                                    1.5 ± 0.2                                                                                  2.1 ± 0.8   4 ± 1    6 ± 1       12 ± 4
  **8a**                                     H                0.35 ± 0.038    2 ± 0.3                                                                              3 ± 0.5                                                                                    7 ± 2       7 ± 1    15 ± 2      54 ± 9
  **8b**                                     F                0.049 ± 0.02    9 ± 1                                                                                9 ± 1                                                                                      8 ± 0.7     24 ± 4   73 ± 8      75 ± 18
  **8c**                                     Cl               0.063 ± 0.08    1 ± 0.2                                                                              14 ± 1                                                                                     0           8 ± 1    23 ± 2      32 ± 4
  **8d**                                     NH~2~            0.25 ± 0.033    2.7 ± 0.3                                                                            1.3 ± 0.3                                                                                  5 ± 2       7 ± 1    9 ± 1       50 ± 6
  **8e**                                     CH~3~O           0.13 ± 0.027    5 ± 0.1                                                                              9 ± 2                                                                                      22 ± 4      14 ± 1   23 ± 6      41 ± 2

All compounds were tested as their (±)-isomers.

The *K*~d~ for (±)-\[^3^H\]epibatidine is 0.02 nM.

Data taken from ref ([@ref21]).

Assessed by comparing the current response to 100 μM of each compound to the mean current response of three preceding applications of ACh, applied at an EC~20~ concentration (20 μM for α4β2, 110 μM for α3β4) or an EC~50~ concentration (300 μM for α7) and expressed as a percentage of the maximal response to ACh.

Assessed by comparing the current response to an EC~50~ concentration of ACh (70 μM for α4β2, 200 μM for α3β4, 300 μM for α7) in the presence of 100 μM of each compound to the mean current response of three preceding applications of ACh alone.

Data taken from ref ([@ref24]).

Substitution of the 4′-pyridyl and 3′-pyridyl rings of analogues **7a** and **8a**, respectively, with 3′- and 4′-substituents, respectively, had only small effects on α4β2\*-nAChR binding affinity. The *K*~i~ values varied from 0.04 to 1.18 nM. With the exception of the 3′-chloro analogue **7c**, all the 3′-substituted 4′-pyridyl analogues **7b**--**e** had very high affinity for α4β2\*-nAChRs. The *K*~i~ values ranged from 0.04 for **7e** to 0.13 nM for **7d**. Even the 3′-chloro substituted analogue had a *K*~i~ value of 1.18 nM. All the 4′-substituted 3′-pyridyl analogues had *K*~i~ values of 0.04--0.35 nM and thus very high affinity for α4β2\*-nAChR. The presence of 3′-substituents on the 4′-pyridyl analogues **7b**--**e** or 4′-substituents on the 3′-pyridyl analogues **8b**--**e** did not show any clear structure affinity patterns. In the case of the **7a**--**e** series, the two highest affinity compounds were the electron-withdrawing 3′-fluoro analogue **7b** (*K*~i~ = 0.067) and the electron-donating methoxy analogue **7e** (*K*~i~ = 0.04). For the 4′-substituted 3′-pyridyl analogues, the 4′-fluoro and 4′-chloro electron-withdrawing analogues **8b** and **8c** (*K*~i~ = 0.049 and 0.063 nM) had higher α4β2\*-nAChR affinity than the 3′-amino and 3′-methoxy electron-donating analogues **8d** and **8e** (*K*~i~ = 0.25 and 0.13 nM). However, all four compounds have subnanomolar *K*~i~ values.

The receptor subtype selectivity of **7a**--**e** and **8a**--**e** was assessed in an electrophysiological assay using rat α4β2-, α3β4-, and α7-nAChRs expressed in *Xenopus* oocytes and assayed by a two-electrode voltage clamp. Compounds were compared to previously determined values for nicotine, nat-epibatidine, varenicline, and compounds **5a** and **5g** (Table [1](#tbl1){ref-type="other"}). Current responses to a high concentration (100 μM) of each compound were compared to the maximum response that can be achieved with acetylcholine. All compounds differed dramatically from nat-epibatidine (a full agonist at α4β2-, α3β4-, and α7-nAChRs). Compounds **7a**, **7c**, **7e**, **8a**, and **8c** displayed little or no agonist activity at α4β2 in this initial screen, while **7b**, **7d**, **8b**, and **8d**--**e** had a low level of agonist activity at this subtype. Compounds **7d** and **8d** had little or no agonist activity at α3β4, while **7a**--**c**, **8a**--**c**, and **8e** had a low level of agonist activity at this subtype. At α7-nAChRs, compounds **7b**, **7e**, and **8c** had little or no agonist activity, compounds **7a**, **7c**--**d**, **8a**--**b**, and **8d** displayed low levels of agonist activity, and compound **8e** showed a moderate level of agonist activity (22 ± 4% of the maximal acetylcholine response). Compounds **7a**--**e** and **8a**--**e** all showed lower agonist activity at α4β2-, α3β4-, and α7-nAChR than did varenicline (a partial agonist at α4β2- and a full agonist at α3β4- and α7-nAChRs).

As an initial screen of antagonist properties, we measured the current response to an EC~50~ concentration of acetylcholine in the presence of 100 μM of each compound and compared this to a preceding current response to acetylcholine alone (Table [1](#tbl1){ref-type="other"}). Compounds **7a**--**e** and **8a**--**e** antagonized, to varying extents, the α4β2-, α3β4-, and α7-nAChR subtypes in this preliminary screen. This contrasts with varenicline, which can antagonize α4β2 receptors but is a full agonist at α3β4- and α7-nAChRs. The ability of **8e** to both activate and antagonize the α7-nAChR subtype indicates that **8e** is a partial agonist at this receptor. The results from this initial screen suggested that some compounds in this series may be selective α4β2 antagonists, and **7a**, **7c**, and **8a** were selected for more detailed studies.

We examined the subtype selectivity of antagonist activity of compounds **7a**, **7c**, and **8a** in more detail by generating concentration--inhibition curves (Table [2](#tbl2){ref-type="other"}) and compared the IC~50~ values to the lead nitro compounds **5a** and **5g**. Compound **7a**, the bioisosteric analogue of **5a**, where the nitro group has been replaced by a pyridine nitrogen, displayed an improved α4β2 selectivity. While **5a** was 2.5-fold selective for α4β2 over α3β4 and 10-fold selective for α4β2 over α7, compound **7a** was 5.7-fold selective for α4β2 over α3β4 and 54-fold selective for α4β2 over α7. Similarly, compound **8a**, the bioisosteric analogue of **5g**, where the nitro group has been replaced by a pyridine nitrogen, displayed an improved α4β2 selectivity. While **5g** was nonselective between α4β2 and α3β4 and 5-fold selective for α4β2 over α7, compound **8a** was 11-fold selective for α4β2 over α3β4 and 58-fold selective for α4β2 over α7. We also examined **7c** but found it to be less selective for α4β2 than was **7a**. None of these compounds was as potent an antagonist as varenicline at α4β2-nAChRs. The ability of these compounds to antagonize α3β4- and α7-nAChRs differs markedly from varenicline, which is a full agonist at these subtypes.

###### Comparison of Antagonist Potency (IC~50~ Values) for Several Epibatidine Analogues at α4β2-, α3β4-, and α7-nAChRs

                antagonist activity[a](#t2fn1){ref-type="table-fn"} IC~50~ (μM)                                               
  ------------- ----------------------------------------------------------------- ------------------------------------------- -----------------------------------------
  varenicline   0.20 ± 0.03[b](#t2fn2){ref-type="table-fn"}                       [d](#t2fn4){ref-type="table-fn"}            [d](#t2fn4){ref-type="table-fn"}
  **5a**        3.2 ± 0.2[c](#t2fn3){ref-type="table-fn"}                         7.9 ± 0.5[c](#t2fn3){ref-type="table-fn"}   32 ± 12[c](#t2fn3){ref-type="table-fn"}
  **5g**        4.3 ± 0.6                                                         3.9 ± 0.3                                   23 ± 5
  **7a**        1.4 ± 0.1                                                         8 ± 1                                       75 ± 16
  **7c**        2.0 ± 0.4                                                         8.8 ± 0.9                                   56 ± 10
  **8a**        1.7 ± 0.2                                                         18 ± 3                                      99 ± 24

Antagonist activity of **7a**, **7c**, and **8a** was assessed in the in vitro electrophysiology assay at a range of concentrations to generate concentration--inhibition curves. Data were fit to the following equation: *I* = *I*~max~/\[1+(IC~50~/*X*)*^n^*\], where *I* is the current response at a compound concentration (*X*), *I*~max~ is the maximum current, IC~50~ is the compound concentration producing half-maximal inhibition of the current response, and *n* is the Hill coefficient.

Data taken from ref ([@ref11]).

Data taken from ref ([@ref24]).

Varenicline is an agonist at α3β4- and α7-nAChRs, with an EC~50~ of 55 ± 8 and 18 ± 6 μM, respectively (ref ([@ref11])).

The 3′-substituted 4′-pyridyl analogues **7a**--**e** and the 4′-substituted 3-pyridyl analogues (**8a**--**e**) were evaluated for their in vivo nAChR properties in mice, and the results were compared to the properties of lead compounds **5a** and **5g** and varenicline (Table [3](#tbl3){ref-type="other"}). Similar to **5a**, the pyridine bioisostere **7a** does not have agonist activity in the tail-flick and hot-plate tests but like **5a** and varenicline did show activity in the hypothermia and spontaneous-activity tests. The ED~50~ values for **7a** in the hypothermia and spontaneous-activity tests were 1.69 and 0.38 mg/kg compared to 0.21 and 0.22 mg/kg for **5a**. Similar to **5a**, **7a** antagonized nicotine-induced antinociception in the tail-flick and hot-plate tests with AD~50~ values of 12 and 290 μg/kg, respectively, compared to 3 and 120 μg/kg for **5a**. Thus, **7a** is a very good bioisostere analogue of **5a**. In contrast, the 3′-pyridyl compound **8a**, which is the pyridine bioisostere of **5g**, was an agonist in all four mice acute tests, whereas **5g** was active only in the spontaneous-activity test. In addition, whereas **5g** was an antagonist of nicotine-induced antinociception in the tail-flick and hot-plate tests with AD~50~ values of 0.5 and 130 μg/kg, respectively, **8a** was an antagonist in only the tail-flick test with an AD~50~ value of 3 μg/kg. Somewhat surprisingly, the in vivo properties of **8a** are quite different from those of **5g**, and thus, even though it is an interesting partial agonist, it is not a good bioisosteric analogue of **5g** in the mice in vivo test. These discrepancies between the in vivo and in vitro effects of **5g** and **8a** could also be related to many factors such as differences in the metabolic profile and brain penetrability of these two analogues as well as the fact that we used expressed receptors systems and not native receptors preparations. Furthermore, since the agonistic response of nicotine in these two tests is largely mediated by α4β2\* nAChR subtypes, it is possible that **5g** and **8a** differ in their affinity/activity at the various α4β2\* nAChR subtypes mediating their pharmacological responses. In addition, in vivo regulation of nicotinic receptors such as α4β2\* nAChR subtypes by these two analogues may differ also. For example, it is possible that, since **5g** was more potent than **8a** as a functional blocker in the tail-flick and hot-plate tests, in vivo desensitization/blockade of α4β2\* receptors by **5g** is more pronounced. We recently reported that varenicline (**3**) and sazetidine, two α4β2\* nicotinic partial agonists that differ in their desensitization properties, differ in their potency to act as functional antagonists of nicotine in these tests.^[@ref30],[@ref31]^

###### Antinociception, Hypothermia, and Spontaneous Activity Profile Data for 2′-Fluoro-3′-(substituted pyridine)deschloroepibatidine Analogues
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                                                                 ED~50~ (mg/kg)         AD~50~ (μg/kg)                                                                      
  ------------------------------------------ -------- ------- --------------------- ---------------------- ---------------------- ----------------------- ----------------- ------------------
   nicotine[b](#t3fn2){ref-type="table-fn"}                      1.3 (0.5--1.8)       0.65 (0.25--0.85)        1.0 (0.6--2.1)        0.5 (0.15--0.78)                                
               nat-epibatidine                                 0.006 (0.001--0.01)   0.004 (0.001--0.008)   0.004 (0.002--0.008)   0.001 (0.0005--0.005)                             
                 varenicline                                        11% @ 10               10% @ 10                 2.8                     2.1                  0.2               470
    **5a**[c](#t3fn3){ref-type="table-fn"}    NO~2~      H           5% @ 10               10% @ 10           0.21 (0.04--1.9)       0.22 (0.04 ± 1.2)       3 (0.8--45)      120 (10--900)
    **5g**[c](#t3fn3){ref-type="table-fn"}      H      NO~2~         3% @ 10               20% @ 10               0% @ 10             6.5 (5.3 ± 8.3)       0.5 (0.3--5)      130 (50--290)
                    **7a**                      H                   13% @ 10               40% @ 10           1.69 (1.1--2.6)         0.38 (0.2--2.7)       12 (10--172)      290 (19--991)
                    **7b**                      F                    5% @ 10               18% @ 10           1.58 (0.97--2.1)       0.17 (0.08--1.5)        4 (0.1--70)     117 (110--1100)
                    **7c**                      Cl                  11% @ 10               19% @ 10           2.74 (1.89--3.5)       1.01 (0.27--3.7)      320 (45--3262)    1370 (180--1430)
                    **7d**                    NH~2~                 11% @ 10               12% @ 10            1.87 (0.1--35)        0.61 (0.04--9.1)        9 (0.4--19)       10% @ 10000
                    **7e**                    CH~3~O                 5% @ 10               10% @ 10           8.5 (1.9--38.6)         1.82 (0.4--8.4)      0.3 (0.02--5.7)     40% @ 10000
                    **8a**                      H                4.9 (3.6--6.7)          5 (3.7--6.7)          3.7 (2.9--4.5)        0.69 (0.4--12.8)        3 (0.5--24)        10% @ 1000
                    **8b**                      F                3.6 (2.7--4.7)        3.27 (2.1--5.3)        0.68 (0.52--1.1)       0.38 (0.13--1.1)         1% @ 100           1% @ 100
                    **8c**                      Cl                  10% @ 10               27% @ 10           3.11 (1.5--5.1)         1.58 (0.5--4.4)         9 (2--38)      2001 (297--3610)
                    **8d**                    NH~2~                  5% @ 10               8% @ 10              2.8 (2--3.8)          184 (0.5--6.3)         30 (3--35)          50% @ 10
                    **8e**                    CH~3~O              4.22 (3--5.3)        1.72 (0.9--3.4)        0.77 (0.51--1.2)       0.53 (0.19--1.1)        21 (3--125)         0% @ 100

All compounds were tested as their (±)-isomers.

Data taken from ref ([@ref21]).

Data taken from ref ([@ref24]).

Similar to the unsubstituted analogue **7a**, none of the 3′-substituted 4-pyridyl analogues **7b**--**e** had any agonist activity in the tail-flick and hot-plate tests (Table [3](#tbl3){ref-type="other"}). In the case of the 4′-substituted 3′-pyridyl analogues, the 4′-fluoro and 4′-methoxy analogues **8b** and **8e** had agonist activity in the tail-flick and hot-plate tests. Similar to **5a**, **5g**, and varenicline, **7b**--**e** and **8b**--**e** had activity in the hypothermia and spontaneous-activity tests.

Analogues **7b**--**e** and **8c**--**e** antagonized nicotine-induced antinociception in the tail-flick test (Table [3](#tbl3){ref-type="other"}). Analogues **7b**--**c** and **8c** also antagonized nicotine-induced antinociception in the hot-plate test with AD~50~ values ranging from 117 to 1370 μg/kg. Compounds **7a** and **7b**, which have AD~50~ values of 290 and 117 μg/kg, respectively, in the hot-plate test, compared to 470 μg/kg for varenicline strongly suggest that these compounds have good brain penetration. Unlike any of the other pyridine substituted analogues, the 3′-fluoro-4′-pyridyl analogue **8b** was an agonist in all four acute mouse tests and had no antagonist properties.

Calculated physicochemical properties such as lipophilicity (clogP), topological polar surface area (TPSA), and derived values such as logBB can be used as an indication of the potential of a compound for development as a CNS drug. These molecular descriptors were calculated for lead compounds **5a** and **5g**, bioisosteric analogues **7a** and **8a**, respectively, as well as compounds **7b**--**e**, **8b**--**e** and reference compounds nicotine, epibatidine, and varenicline (Table [4](#tbl4){ref-type="other"}). In general, CNS drugs have a clogP in the range 2--4,^[@ref32]^ TPSA less than 76 Å,^[@ref33]^ and logBB greater than −1.^[@ref34]^ All of the compounds have clogP values within or close to the desirable range and logBB values between −0.54 and +0.08. In addition, all of the compounds have TPSA values of less than 76 Å. A comparison of the logP, TPSA, and logBB values of 1.99, 37.81, and −0.12, respectively, for bioisosteric analogues **7a** and **8a** to the corresponding values of 3.14, 70.74, and −0.43 for lead compounds **5a** and **5g** show that these two bioisosteric analogues (**7a** and **8a**) have at least as favorable if not better calculated physicochemical properties than lead compounds **5a** and **5g**. In addition, both **7a** and **8a** have calculated logBB values somewhat better than that of varenicline.

###### Calculated Physiochemical Properties of **5a**, **5g**, **7a**--**e**, **8a**--**e**, Nicotine, Nat Epibatidine, and Varenicline

  compd         logP[a](#t4fn1){ref-type="table-fn"}   TPSA[a](#t4fn1){ref-type="table-fn"}   logBB[b](#t4fn2){ref-type="table-fn"}
  ------------- -------------------------------------- -------------------------------------- ---------------------------------------
  nicotine      1.16                                   16.13                                  0.08
  epibatidine   1.84                                   24.92                                  0.05
  varenicline   1.01                                   37.81                                  --0.27
  **5a**        3.14                                   70.74                                  --0.43
  **5g**        3.14                                   70.74                                  --0.43
  **7a**        1.99                                   37.81                                  --0.12
  **7b**        2.52                                   37.81                                  --0.04
  **7d**        1.75                                   63.83                                  --0.54
  **7c**        2.81                                   37.81                                  0.01
  **7e**        2.12                                   37.81                                  --0.10
  **8a**        1.99                                   37.81                                  --0.12
  **8b**        2.52                                   37.81                                  --0.04
  **8c**        2.81                                   37.81                                  0.01
  **8d**        1.75                                   63.83                                  --0.54
  **8e**        2.42                                   47.04                                  --0.19

ChemAxon Calculator Plugins, Marvin 6.1.0, 2013.

logBB = −0.0148 × TPSA + 0.152 × clogP + 0.139 (from ref ([@ref34])).

In summary, 2′-fluoro-3-(substituted pyridine)epibatidine analogues **7a**--**e** and **8a**--**e** were synthesized and evaluated for the ability to inhibit \[^3^H\]epibatidine binding to nAChR, tested for agonist and antagonist activity at α4β2-, α3β4-, and α7-nAChR in an electrophysiology assay, and evaluated for agonist effects in the tail-flick, hot-plate, spontaneous-activity, and hypothermia tests in the mouse and as antagonists of nicotine-induced antinociception in the tail-flick and hot-plate tests in the mouse. A comparison of the nAChR binding and electrophysiology of bioisosteres **7a** and **8a** to those of the nitrophenyl lead compounds **5a** and **5g**, respectively, showed that **7a** and **8a** had in vitro nAChR properties similar to those of **5a** and **5g** but were more selective for the α4β2-nAChR relative to the α3β4- and α7-nAChRs than **5a** and **5g**. Similar to **5a**, **7a** did not have agonist activity in the tail-flick and hot-plate tests and like **5a** was a potent antagonist of nicotine-induced antinociception in these two tests. Thus, **7a** is a very good bioisosteric analogue of **5a**. In contrast, **8a** unlike **5g** was an agonist in both the tail-flick and hot-plate tests and was an antagonist of nicotine-induced antinociception only in the tail-flick test, whereas **5g** was an antagonist in both tests. Even though **8a** is not a good bioisosteric analogue of **5g** in the mice test, it is an interesting partial agonist. A comparison of the AD~50~ value of **7a** to that of varenicline in the hot-plate test, strongly suggest that this compound penetrates the brain in mice. Calculated logBB values for **7a** and **8a** also suggest that this compound will have good blood--brain barrier penetration. Since both nAChR antagonists and partial agonists are of interest as possible pharmacotherapies for treating smokers, both **7a** and **8a** are candidates for development as pharmacotherapies to treat nicotine addiction.

Experimental Section {#sec3}
====================

Melting points were determined on a Mel-temp (Laboratory Devices, Inc.) capillary tube apparatus. NMR spectra were recorded on a Bruker Avance 300 or AMX 500 spectrometer using tetramethylsilane as internal standard. Mass spectra were determined on a Perkin--Elmer Sciex API 150EX mass spectrometer outfitted with APCI and ESI sources. Melting point was determined on a Laboratory Devices MEL-TEMP II. Elemental analyses were carried out by Atlantic Microlab, Inc., Norcross GA. The purity of the compounds (\>95%) was established by elemental analysis. Analytical thin-layer chromatography (TLC) was carried out on plates precoated with silica gel (60 F~254~). TLC visualization was accomplished with a UV lamp or in an iodine chamber. Purifications by flash chromatography were performed on a Combiflash Teledyne ISCO instrument.

Suzuki Cross-Coupling Reaction: General Procedure (Method A) {#sec3.1}
------------------------------------------------------------

To a resealable reaction vessel under nitrogen was added 1.0 equiv of 7-*tert*-butoxycarbonyl-2-*exo*-(2′-amino-3′-bromo-5′-pyridinyl)-7-azabicyclo\[2.2.1\]heptane (**9**), Pd(OAc)~2~ (0.1 equiv), P(*o*-tolyl)~3~ (0.2 equiv), sodium carbonate (2.0 equiv) and the respective pyridinyl boronic acid (1.6 equiv), DME (6 mL), and water (0.7 mL). The mixture was degassed through bubbling nitrogen, sealed, and heated on a sand bath at 80 °C for 5 h. The mixture was cooled, poured into 20 mL of a saturated aqueous solution of NaHCO~3~, and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~ and filtered through Celite, and the solvent was removed under reduced pressure. The resultant residue was purified on silica gel by flash chromatography eluted with CHCl~3~--MeOH (50:1 to 10:1).

Suzuki Cross-Coupling Reaction: General Procedure (Method B) {#sec3.2}
------------------------------------------------------------

To a resealable reaction vessel under nitrogen was added 1.0 equiv of the 3′-bromo compound **9**, Pd(PPh~3~)~4~ (10 mol %), K~2~CO~3~ (2.0 equiv) and the respective pyridinyl boronic acid (1.3 equiv), toluene (12 mL), ethanol (1.5 mL), and water (1.5 mL). The mixture was degassed through bubbling nitrogen, sealed, and heated on a sand bath at 110 °C. After 24 h, the mixture was cooled, poured into 30 mL of H~2~O, and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~ and filtered through Celite, and the solvent was removed in vacuo. The resultant residue was purified by flash chromatography on a silica gel column using hexanes--isopropanol (80:20 to 25:75) or CHCl~3~--MeOH (30:1 to 10:1) as the eluent.

General Procedure C: Removal of the Boc-Protecting Group {#sec3.2.1}
--------------------------------------------------------

A solution of the Boc-protected compound in methylene chloride (5 mL) was treated with TFA (1.5 mL) and stirred at room temperature overnight. In some cases the solution was heated at 40 °C for 2 h and then stirred at room temperature overnight. The solvent was then removed in vacuo, and the residue was treated with a solution of NH~4~Cl (20 mL) and extracted with CHCl~3~--MeOH (10%) (3 × 30 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered, and concentrated in vacuo, and the residue was purified by flash chromatography using a silica gel column eluted with CHCl~3~--MeOH (10%) to provide the respective amine.

2-*exo-*\[2′-Fluoro-3′-(pyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**7a**) Fumarate {#sec3.3}
---------------------------------------------------------------------------------------------------

A solution of **12a** (378 mg, 1.03 mmol, 1.0 equiv) in 70% HF in pyridine (1.5 mL) was stirred at 0 °C for 30 min. Sodium nitrite (806 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on a silica gel column using CHCl~3~--MeOH as the eluent to provide 192 mg (69%) of **7a** as a colorless oil. ^1^H NMR (300 MHz, CD~3~OD) δ 1.50--1.78 (m, 6H), 2.01--2.08 (dd, *J* = 9.0, 11.2 Hz, 1H), 3.02--3.07 (dd, *J* = 8.7, 5.2 Hz, 1H), 3.66 (s, 1H), 3.77 (br s, 1H), 7.70--7.73 (m, 2H), 8.13 (dd, *J* = 2.4, 9.4 Hz, 1H), 8.18 (s, 1H), 8.64 (d, *J* = 1.5 Hz, 1H), 8.65 (d, *J* = 1.5 Hz, 1H); ^13^C NMR (CD~3~OD) δ 30.0, 31.8, 41.1, 45.7, 57.9, 63.7, 121.2, 125.1, 141.3, 142.1, 144.2, 147.8, 148.0, 150.6, 158.6, 161.7; MS (ESI) *m*/*z* 270.2 (M + H)^+^.

A solution of **7a** (302 mg, 1.12 mmol) in chloroform (2 mL) was placed in vial and treated with 1.1 equiv of fumaric acid (0.65 M in MeOH). After 24 h, the white solid obtained was recrystallized from a MeOH--Et~2~O mixture to provide the salt **7a**·C~4~H~4~O~4~ as a white solid: mp 192--195 °C. ^1^H NMR (300 MHz, CD~3~OD) δ 1.86--2.22 (m, 6H), 2.44--2.51 (dd, *J* = 9.0, 11.0 Hz, 1H), 3.50--3.55 (m, 1H), 4.35 (br s, 1H), 4.56 (d, *J* = 3.9 Hz, 1H), 6.63 (s, 1H), 7.72--7.75 (m, 2H), 8.20 (dd, *J* = 2.4, 9.0 Hz, 1H), 8.27 (d, *J* = 2.4 Hz, 1H), 8.67 (m, *2*H); ^13^C NMR (CD~3~OD) δ 27.0, 29.0, 37.7, 43.4, 60.2, 64.1, 121.6, 125.1, 136.2, 137.6, 141.3, 143.9, 147.8, 148.0, 150.7, 159.0, 162.2, 171.4; MS (ESI) *m*/*z* 270.1 \[(M -- fumaric)^+^, M = C~16~H~16~FN~3~·C~4~H~4~O~4~\]. Anal. (C~20~H~20~FN~3~O~4~·0.25 H~2~O) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(2-fluoropyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**7b**) Fumarate {#sec3.4}
-----------------------------------------------------------------------------------------------------------

A solution of **12b** (230 mg, 0.60 mmol, 1.0 equiv) in 70% HF in pyridine (1.5 mL) was stirred at 0 °C for 30 min. Sodium nitrite (413 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on a silica gel column using CHCl~3~--MeOH as the eluent to provide 121 mg (70%) of **7b** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.56--1.68 (m, 6H), 1.92--1.98 (dd, *J* = 9.1, 11.2 Hz, 1H), 2.81--2.86 (m, 1H), 3.60 (s, 1H), 3.83 (br s, 1H), 7.17 (d, *J* = 1.0 Hz, 1H), 7.43 (ddd, *J* = 1.6, 4.9, 6.9 Hz, 1H), 8.15--8.19 (m, 2H), 8.23 (d, *J* = 5.3 Hz, 1H); ^13^C NMR (CDCl~3~) δ 30.4, 31.5, 40.7, 44.2, 56.4, 62.9, 109.0, 119.4, 121.1, 139.6, 141.5, 147.5, 157.1, 160.3, 162.6, 162.7; MS (ESI) *m*/*z* 288.3 (M + H)^+^.

A solution of **7b** (141 mg, 0.49 mmol) in CH~2~Cl~2~ in a vial was treated with 1.2 equiv of fumaric acid (0.65 M) in MeOH, and the vial was allowed to stand in a refrigerator overnight. The excess solvent was then removed in vacuo from the salt and then redissolved in a minimal amount of MeOH, and the fumarate salt was recrystallized from MeOH using diethyl ether to provide 110 mg (55%) of the salt **7b**·C~4~H~4~O~4~ as a white crystalline solid: mp 203--205 °C. ^1^H NMR (500 MHz, CD~3~OD) δ 1.87--2.20 (m, 5H), 2.45--2.50 (dd, *J* = 9.3, 13.2 Hz, 1H), 3.50--3.53 (m, 1H), 4.34--4.35 (br s, 1H), 4.56 (d, *J* = 3.9 Hz, 1H), 6.64 (s, 2H), 7.41 (s, 1H), 7.61--7.63 (m, 1H), 8.21 (dd, *J* = 2.4, 9.3 Hz, 1H), 8.28 (d, *J* = 1.0 Hz, 1H), 8.32 (d, *J* = 5.3 Hz, 1H); ^13^C NMR (CD~3~OD) δ 25.8, 27.8, 36.5, 42.2, 59.0, 62.8, 109.4, 121.6, 135.0, 136.5, 140.1, 147.2, 147.8, 158.3, 160.2, 163.4, 165.3, 170.2; MS (ESI) *m*/*z* 288.3 \[(M -- fumaric)^+^, M = C~16~H~15~F~2~N~3~**·**C~4~H~4~O~4~\]. Anal. (C~20~H~19~F~2~N~3~O~4~) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(2-chloropyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**7c**) Fumarate {#sec3.5}
-----------------------------------------------------------------------------------------------------------

A solution of **12c** (130 mg, 0.32 mmol, 1.0 equiv) in 70% HF in pyridine (1.5 mL) was stirred at 0 °C for 30 min. Sodium nitrite (224 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on a silica gel column using CHCl~3~--MeOH as the eluent to provide 86 mg (87%) of **7c** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.54--1.67 (m, 6H), 1.92--1.98 (dd, *J* = 9.1, 11.2 Hz, 1H), 2.81--2.86 (m, 1H), 3.60 (s, 1H), 3.83 (br s, 1H), 7.46 (dd, *J* = 1.2, 5.2 Hz, 1H), 7.56 (s, 1H), 8.12--8.15 (m, 2H), 8.47 (d, *J* = 5.2 Hz, 1H); ^13^C NMR (CDCl~3~) δ 30.4, 31.6, 40.7, 44.3, 56.4, 62.9, 119.2, 122.1, 139.6, 141.5, 145.1, 147.2, 149.9, 152.1, 157.1, 160.3; MS (ESI) *m*/*z* 304.3 (M + H)^+^.

A solution of **7c** (106 mg, 0.35 mmol) in CH~2~Cl~2~ in a vial was treated with 1.2 equiv of fumaric acid (0.65 M) in MeOH, and the vial was allowed to stand in a refrigerator overnight. The excess solvent was then removed in vacuo from the salt and then redissolved in a minimal amount of MeOH, and the fumarate salt was recrystallized from MeOH using diethyl ether to provide 62 mg (42%) of the salt **7c**·C~4~H~4~O~4~ as a white crystalline solid: mp 193--194 °C. ^1^H NMR (500 MHz, CD~3~OD) δ 1.87--2.21 (m, 5H), 2.45--2.50 (dd, *J* = 9.2, 13.2 Hz, 1H), 3.50--3.53 (m, 1H), 4.34--4.35 (br s, 1H), 4.56 (d, *J* = 3.9 Hz, 1H), 6.63 (s, 2H), 7.67 (dd, *J* = 1.4, 9.3 Hz, 1H), 7.80 (s, 1H), 8.21 (dd, *J* = 2.4, 9.3 Hz, 1H), 8.28 (d, *J* = 2.4 Hz, 1H), 8.48 (d, *J* = 4.9 Hz, 1H); ^13^C NMR (CD~3~OD) δ 25.7, 27.8, 36.5, 42.2, 59.0, 62.9, 119.4, 122.7, 135.0, 136.6, 140.1, 145.4, 147.3, 149.9, 151.8, 158.3, 160.3, 170.1; MS (ESI) *m*/*z* 304.0 \[(M -- fumaric)^+^, M = C~16~H~15~ClFN~3~·C~4~H~4~O~4~\]. Anal. (C~20~H~19~ClFN~3~O~4~·0.25 H~2~O) C, H, N.

2-Fluoro-3-(2′-amino-4′-pyridinyl)deschloroepibatidine (**7d**) Hydrochloride {#sec3.6}
-----------------------------------------------------------------------------

A solution of 2-amino-4-bromopyridine (200 mg, 1.16 mmol, 1.0 equiv), bispinacolato diborane (307 mg, 1.21 mmol, 1.05 equiv), Pd~2~dba~3~ (36 mg, 0.035 mmol, 3 mol %), Xphos (88 mg, 0.185 mmol, 16 mol %), and KOAc (272 mg, 2.77 mmol, 2.4 mmol) in dioxane placed in a resealable pressure vessel was degassed through bubbling nitrogen for 40 min then heated at 110 °C for 4 h. A TLC check revealed that all the bromopyridine had been converted to the boronic ester. The reaction was allowed to cool to room temperature, and K~3~PO~4~ (613 mg, 2.89 mmol, 2.5 equiv), a solution of **10** (270 mg, 1.0 mmol, 0.87 equiv) in dioxanes, an additional 3 mol % of Pd~2~dba~3~, and H~2~O (1 mL) were added to the reaction. The mixture was degassed for 30 min and heated for 18 h at 110 °C. The reaction was cooled to room temperature and extracted with EtOAC (3 × 30 mL). The combined organic layers were dried over MgSO~4~ and filtered through Celite, and the solvent was removed in vacuo. Two purifications of the residue by flash chromatography through an ISCO column using CHCl~3~--MeOH (10:1) as the eluent provided 60 mg (21%) of **7d** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.51--1.71 (m, 5H), 1.90--1.97 (m, 1H), 2.36 (br s, 1H), 2.80--2.85 (dd, *J* = 3.8, 5.0 Hz, 1H), 3.61 (s, 1H), 3.81 (d, *J* = 2.7 Hz, 1H), 4.66 (br s, 2H), 6.72 (s, 1H), 6.84 (d, *J* = 5.3 Hz, 1H), 8.02 (dd, *J* = 2.3, 9.5 Hz, 1H), 8.11 (s, 1H), 8.13 (d, *J* = 5.7 Hz, 1H); ^13^C NMR (CDCl~3~) δ 30.2, 31.4, 40.5, 44.3, 56.5, 62.9, 108.1, 113.9, 139.4, 140.6, 143.7, 145.9, 148.5, 157.4, 158.8, 160.6; MS (ESI) *m*/*z* 285.5 (M + H)^+^.

A solution of **7d** (122 mg, 0.43 mmol) in chloroform in a vial was treated with a 2.0 equiv solution of HCl in diethyl ether and allowed to stand at room temperature. The excess solvent was filtered off, and the obtained salt was washed with ether and then dried to provide 94 mg of the salt **7d·**HCl as a white solid: mp 205--208 °C. ^1^H NMR (300 MHz, CD~3~OD) δ 1.83--2.28 (m, 5H), 2.46--2.53 (dd, *J* = 3.8, 9.6 Hz, 1H), 3.52--3.57 (dd, *J* = 3.1, 5.5 Hz, 1H), 4.37 (d, *J* = 3.6 Hz, 1H), 4.59 (d, *J* = 2.7 Hz, 1H), 7.02--7.05 (dd, *J* = 1.6, 6.1 Hz, 1H), 7.10 (s, 1H) 7.98 (d, *J* = 6.1 Hz, 1H) 8.16 (dd, *J* = 2.3, 9.2 Hz, 1H) 8.28 (s, 1H); ^13^CNMR (CD~3~OD) δ 26.8, 28.9, 37.5, 43.3, 60.5, 64.2, 112.0, 113.8, 137.4, 141.3, 143.2, 148.0, 148.2, 158.8, 158.9, 162.1; MS (ESI) *m*/*z* 285.7 \[(M -- HCl)^+^, M = C~16~H~17~FN~4~**·**2HCl\]. Anal. (C~16~H~19~Cl~2~FN~4~) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(2-methoxypyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**7e**) Fumarate {#sec3.7}
------------------------------------------------------------------------------------------------------------

To a resealable reaction pressure vessel under nitrogen was added compound **10** (180 mg, 0.66 mmol, 1.0 equiv), compound **16** (188 mg, 0.80 mmol, 1.2 equiv), (Pd(PPh~3~)~4~ (38 mg, 0.03 mmol, 5 mol %), K~2~CO~3~ (184 mg, 1.33 mmol, 2.0 equiv), 1,4-dioxane (10 mL), and water (0.80 mL). The reaction mixture was degassed through bubbling nitrogen for 40 min, sealed, and heated over a sand bath at 110 °C for 18 h. After cooling, the solvent was removed under reduced pressure, and to the residue was added 20 mL of H~2~O. The organic product was extracted using EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~ and filtered through Celite, and the solvent was removed in vacuo. Purification by flash chromatography on silica gel using MeOH--CHCl~3~ as the eluent provided 100 mg (50%) of **7e** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.51--1.68 (m, 5H), 1.89--1.96 (dd, 3.8, 9.6 Hz, 1H), 1.98 (broad signal 1H), 2.79--2.84 (dd, *J* = 3.4, 5.5 Hz, 1H), 3.59 (s, 1H), 3.81 (s, 1H), 3.96 (s, 3 H), 6.96 (s, 1H), 7.07--7.10 (dt, *J* = 5.3, 1.5 Hz, 1H), 8.06 (dd, *J* = 2.4, 9.6 Hz, 1H), 8.11 (s, 1H), 8.21 (d, *J* = 5.3 Hz, 1H); ^13^C NMR (CDCl~3~) δ 30.2. 31.4, 40.5, 44.3, 53.5, 56.4, 62.9, 110.5, 116.6, 139.6, 140.8, 144.6, 146.2, 146.4, 147.2, 160.5, 164.6; MS (ESI) *m*/*z* (300.4) (M + H)^+^.

A solution of **7e** (156 mg, 0.52 mmol) in CH~2~Cl~2~ in a vial was treated with 1.2 equiv of fumaric acid (0.65 M) in MeOH, and the vial was allowed to stand in a refrigerator overnight. The excess solvent was then removed in vacuo from the salt that was then redissolved in a minimal amount of MeOH, and the fumarate salt was recrystallized from MeOH using diethyl ether to provide 164 mg (74%) of the salt **7e**·C~4~H~4~O~4~ as a white solid: mp 160--164 °C. ^1^H NMR (300 MHz, CD~3~OD) δ 1.85--2.19 (m, 5H), 2.43--2.50 (dd, *J* = 9.3, 13.2 Hz, 1H), 3.48--3.53 (m, 1H), 3.96 (s, 3H), 4.34 (br s, 1H), 4.55 (s, 1H), 6.65 (s, 2H), 7.07 (s, 1H), 7.22 (dd, *J* = 1.2, 4.1 Hz, 1H), 8.12 (d, *J* = 9.2 Hz, 1H), 8.22--8.23 (m, 2H); ^13^C NMR (CD~3~OD) δ 26.9, 29.0, 37.7, 43.4, 54.2, 60.2, 64.1, 111.6, 117.9, 136.1, 137.5, 141.2, 145.9, 147.5, 147.6, 148.3, 162.2, 166.2, 171.1; MS (ESI) *m*/*z* 300.3 \[(M -- fumaric)^+^, M = C~17~H~18~FN~3~O·C~4~H~4~O~4~\]. Anal. (C~21~H~22~FN~3~O~5~) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(pyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**8a**) Hemifumarate {#sec3.8}
-------------------------------------------------------------------------------------------------------

A solution of **11a** (394 mg, 1.08 mmol, 1.0 equiv) in 70% HF in pyridine (1.5 mL) was stirred at 0 °C for 30 min. Sodium nitrite (742 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (40 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using CHCl~3~--MeOH as the eluent to provide 203 mg (70%) of **8a** as a colorless oil. ^1^H NMR (300 MHz, CD~3~OD) δ 1.49--1.79 (m, 6H), 2.01--2.08 (dd, *J* = 9.1, 11.2 Hz, 1H), 3.02--3.07 (dd, *J* = 3.3, 5.4 Hz, 1H), 3.67 (s, 1H), 3.77 (br s, 1H), 7.54 (dd, *J* = 2.6, 7.8 Hz, 1H), 8.08--8.15 (m, 3H), 8.58--8.60 (d, 2H), 8.58 (d, *J* = 1.4 Hz, 1H), 8.80 (s, 1H); ^13^C NMR (CD~3~OD) δ 29.9, 31.8, 40.6, 41.1, 45.7, 57.8, 63.9, 121.1, 125.2, 138.4, 141.4, 142.0, 147.0, 150.1, 158.7, 161.8; MS (ESI) *m*/*z* 270.3 (M + H)^+^.

A solution of **8a** (246 mg, 0.91 mmol) in chloroform (2 mL) was placed in vial and treated with 1.1 equiv of fumaric acid (0.65 M in MeOH). After 24 h, the white solid obtained was recrystallized from MeOH using Et~2~O to provide the salt **8a·**0.5C~4~H~4~O~4~ as a white solid: mp 155--159 °C. ^1^H NMR (300 MHz, CD~3~OD) δ 1.86--2.22 (m, 6H), 2.44--2.51 (dd, *J* = 9.0, 11.0 Hz, 1H), 3.49--3.54 (dd, *J* = 3.0, 5.1 Hz, 1H), 4.35 (br s, 1H), 4.56 (d, *J* = 3.9 Hz, 1H), 6.63 (s, 1H), 7.56--7.60 (dd, *J* = 2.3, 7.5 Hz, 1H), 8.12--8.16 (m, 2H), 8.23 (s, 1H), 8.61 (dd, *J* = 1.4, 6.0 Hz, 1H), 8.81 (s, 1H); ^13^C NMR (CD~3~OD) δ 27.4, 29.4, 38.2, 43.8, 59.8, 64.0, 121.0, 125.4, 136.8, 138.2, 138.5, 141.4, 147.0, 147.2, 150.0, 159.1, 162.3, 171.5; MS (ESI) *m*/*z* 270.2 \[(M -- fumaric)^+^, M = C~16~H~16~FN~3~**·**0.5C~4~H~4~O~4~\]. Anal. (C~18~H~18~FN~3~O~2~·0.5 H~2~O) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(6-fluoropyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**8b**) Hemifumarate {#sec3.9}
---------------------------------------------------------------------------------------------------------------

Compound **11b** (250 mg, 0.65 mmol, 1.0 equiv) was placed in a plastic vessel and was treated dropwise with 1.5 mL of 70% HF in pyridine, and the mixture was stirred at 0 °C for 30 min. Sodium nitrite (449 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (40 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using CHCl~3~--MeOH as the eluent to provide 170 mg (91%) of **8b** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.54--1.70 (m, 6H), 1.92--1.99 (dd, *J* = 9.0, 11.2 Hz, 1H), 2.82--2.87 (m, 1H), 3.61 (s, 1H), 3.83 (br s, 1H), 7.04 (dd, *J* = 3.0, 8.4 Hz, 1H), 7.99--8.09 (m, 2H), 8.14 (br s, 1H), 8.42 (d, *J* = 0.8 Hz, 1H); ^13^C NMR (CDCl~3~) δ 30.3, 31.5, 40.6, 44.3, 56.4, 62.9, 109.3, 118.5, 139.5, 141.3, 145.8, 147.5, 157.3, 160.4, 161.7, 164.9; MS (ESI) *m*/*z* 288.3 (M + H)^+^.

A solution of **8b** (198 mg, 0.69 mmol) in chloroform (2 mL) was placed in a vial and treated with 1.1 equiv of fumaric acid (0.65 M in MeOH). After 24 h, the white solid obtained was recrystallized from MeOH using Et~2~O to provide 200 mg (84%) of the salt **8b**·0.5C~4~H~4~O~4~ as a white crystalline solid: mp 197--199 °C. ^1^H NMR (500 MHz, CD~3~OD) δ 1.81--2.15 (m, 5H), 2.38--2.43 (dd, *J* = 9.3, 13.2 Hz, 1H), 3.42--3.46 (m, 1H), 4.43 (br s, 1H), 6.57 (s, 1H), 7.21 (dd, *J* = 2.4, 8.3 Hz, 1H), 8.14 (dd, *J* = 2.4, 8.2 Hz, 1H), 8.21--8.25 (m, 2H), 8.48 (br s, 1H); ^13^C NMR (CD~3~OD) δ 27.5, 29.5, 38.3, 43.8, 59.9, 64.1, 111.0, 120.5, 137.0, 141.4, 143.8, 147.2, 148.8, 159.7, 161.6, 164.1, 166.0, 174.0; MS (ESI) *m*/*z* 288.3 \[(M -- fumaric)^+^, M = C~16~H~15~F~2~N~3~·0.5C~4~H~4~O~4~\]. Anal. (C~18~H~17~F~2~N~3~O~2~) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(6-chloropyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**8c**) Fumarate {#sec3.10}
-----------------------------------------------------------------------------------------------------------

Compound **11c** (300 mg, 0.75 mmol, 1.0 equiv) was placed in a plastic vessel and was treated dropwise with 3 mL of 70% HF in pyridine, and the mixture was stirred at 0 °C for 30 min. Sodium nitrite (559 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (40 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using CHCl~3~--MeOH as the eluent to provide 142 mg (62%) of **8c** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.54--1.71 (m, 6H), 1.92--1.98 (dd, *J* = 9.1, 11.2 Hz, 1H), 2.81--2.86 (m, 1H), 3.61 (s, 1H), 3.81 (br s, 1H), 7.42 (dd, *J* = 0.6, 8.3 Hz, 1H), 7.88 (ddd, *J* = 0.8, 4.1, 8.3 Hz, 1H), 8.06 (dd, *J* = 2.4, 9.6 Hz, 1H), 8.15 (br s, 1H), 8.58 (br s, 1H); ^13^C NMR (CDCl~3~) δ 30.4, 31.5, 40.6, 44.3, 56.4, 62.9, 118.5, 124.1, 129.2, 139.5, 141.3, 146.1, 149.2, 151.2, 157.3, 160.5; MS (ESI) *m*/*z* 304.3 (M + H)^+^.

A solution of **8c** (138 mg, 0.46 mmol) in chloroform (2 mL) was placed in a vial and treated with 1.1 equiv of fumaric acid (0.65 M in MeOH). After 24 h, the white solid obtained was recrystallized from MeOH using Et~2~O to provide 105 mg (55%) of the salt of **8c**·0.5C~4~H~4~O~4~ as a white crystalline solid: mp 194--195 °C. ^1^H NMR (500 MHz, CD~3~OD) δ 1.89--2.20 (m, 5H), 2.45--2.49 (dd, *J* = 9.2, 13.2 Hz, 1H), 3.49--3.52 (dd, *J* = 3.5, 9.5 Hz, 1H), 4.34 (br s, 1H), 4.56 (d, *J* = 3.5 Hz, 1H), 6.63 (s, 2H), 7.60 (d, *J* = 8.5 Hz, 1H), 8.09--8.15 (m, 2H), 8.23 (d, *J* = 2.4 Hz, 1H), 8.64 (br s, 1H); ^13^C NMR (CD~3~OD) δ 27.1, 29.1, 37.8, 43.5, 60.3, 64.2, 120.4, 125.8, 130.6, 136.3, 137.8, 141.3, 147.4, 150.6, 152.6, 159.8, 161.7, 171.5; MS (ESI) *m*/*z* 304.5 \[(M -- fumaric)^+^, M = C~16~H~15~ClFN~3~·C~4~H~4~O~4~\]. Anal. (C~20~H~19~ClFN~3~O~4~) C, H, N.

2′-Fluoro-3′-(2″-amino-5″-pyridinyl)deschloroepibatidine (**8d**) Hydrochloride {#sec3.11}
-------------------------------------------------------------------------------

To a resealable reaction pressure vessel under nitrogen was added 2-*exo*-(2′-fluoro-3′-bromo)-7-azabicyclo\[2.2.1\]heptane (**10**) (125 mg, 0.46 mmol, 1.0 equiv), Pd(PPh~3~)~4~ (27 mg, 5 mol %), K~2~CO~3~ (128 mg, 0.92 mmol, 2.0 equiv), 1,4-dioxane (10 mL), water (0.80 mL), and 2-aminopyridine-5-pinacolate boronic ester (122 mg, 0.55 mmol, 1.2 equiv). The mixture was degassed through bubbling nitrogen for 40 min and heated at 110 °C for 18 h. After cooling, the solvent was removed under reduced pressure, and to the residue was added 20 mL of H~2~O. The organic product was extracted using EtOAc (3 × 30 mL). The combined organic layers were dried over Na~2~SO~4~ and filtered through Celite, and the solvent was removed in vacuo. Purification by flash chromatography on silica gel using MeOH--CHCl~3~ as the eluent provided 88 mg (67%) of the desired product **8d** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.47--1.67 (m, 5H), 1.85--1.92 (m, 2H), 2.76--2.80 (dd, *J* = 3.8, 5.0 Hz, 1H), 3.56 (s, 1H), 3.75 (d, *J* = 2.7 Hz, 1H), 4.82 (s, 2H), 6.53 (d, *J* = 8.6 Hz, 1H), 7.63 (dt, *J* = 1.9, 8.6 Hz, 1H), 7.87 (dd, *J* = 2.3, 9.5 Hz, 1H), 7.98 (s, 1H), 8.23 (s, 1H); ^13^CNMR (CDCl~3~) δ 30.2, 31.4, 40.5, 44.5, 56.4, 62.8, 108.2, 120.2, 138.0, 138.7, 140.7, 144.2, 147.9, 157.5, 158.3, 160.6; MS (ESI) *m*/*z* 285.7 (M + H)^+^.

A solution of the diamine **8d** (217 mg, 0.76 mmol) in chloroform in a vial was treated with a 2.0 equiv solution of HCl in diethyl ether and allowed to stand at room temperature. The excess solvent was filtered off, and the obtained salt washed with ether and then dried to provide 246 mg (90%) of **8d**·HCl as a white solid: mp 202--205 °C. ^1^H NMR (300 MHz, CD~3~OD) δ 1.88--2.24 (m, 5H), 2.44--2.52 (dd, *J* = 3.8, 9.6 Hz, 1H), 3.51--3.56 (dd, *J* = 3.1, 5.5 Hz, 1H), 4.37 (d, *J* = 3.4 Hz, 1H), 4.58 (d, *J* = 2.7 Hz, 1H), 7.11 (dd, *J* = 1.9, 8.2 Hz, 1H), 8.18--8.28 (m, 4H); ^13^CNMR (CD~3~OD) δ 26.8, 28.9, 37.6, 43.3, 60.5, 64.4, 114.7, 119.3, 120.4, 137.6, 140.6, 145.1, 147.2, 155.8, 158.9, 162.1; MS (ESI) *m*/*z* 285.6 \[(M -- HCl)^+^, M = C~16~H~17~FN~4~**·**2HCl\]. Anal. (C~16~H~19~Cl~2~FN~4~·1.25 H~2~O) C, H, N.

2-*exo-*\[2′-Fluoro-3′-(6-methoxypyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**8e**) Hemifumarate {#sec3.12}
----------------------------------------------------------------------------------------------------------------

Compound **11d** (480 mg, 1.21 mmol, 1.0 equiv) was placed in a plastic vessel and was treated dropwise with 3 mL of 70% HF in pyridine, and the mixture was stirred at 0 °C for 30 min. Sodium nitrite (835 mg, 10 equiv) was added in small portions, and the reaction mixture was stirred at room temperature. After 1 h, the mixture was poured into a 1:1 aqueous solution of NH~4~OH--H~2~O (100 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over anhydrous Na~2~SO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using CHCl~3~--MeOH as the eluent to provide 227 mg (94%) of **8e** as a colorless oil. ^1^H NMR (300 MHz, CD~3~OD) δ 1.48--1.76 (m, 6H), 1.94--2.05 (m, 2H), 2.96--3.01 (dd, *J* = 3.4, 5.5 Hz, 1H), 3.65 (s, 3H), 3.77 (br s, 1H), 6.83 (d, *J* = 8.7 Hz, 1H), 7.88 (tt, *J* = 0.7, 1.7, 8.7 Hz, 1H), 7.99 (dd, *J* = 2.4, 9.6 Hz, 1H), 8.04 (d, *J* = 0.8 Hz, 1H), 8.34 (d, *J* = 1.6 Hz, 1H); ^13^C NMR (CD~3~OD) δ 29.9, 31.7, 40.9, 45.7, 54.3, 57.7, 63.7, 111.7, 121.3, 124.5, 140.8, 141.6, 145.8, 147.9, 158.6, 161.8, 165.5; MS (ESI) *m*/*z* 300.3 (M + H)^+^.

A solution of **8e** (169 mg, 0.53 mmol) in CH~2~Cl~2~ in a vial was treated with a 1.2 equiv of fumaric acid (0.65 M) in MeOH, and the vial was allowed to stand in a refrigerator overnight. The excess solvent was removed in vacuo from the salt that was then redissolved in a minimal amount of MeOH, and the fumarate salt was recrystallized from MeOH using diethyl ether to provide 159 mg of the salt **8e**·0.5C~4~H~4~O~4~: mp 193--195 °C. ^1^H NMR (300 MHz, methanol-*d*~4~) δ 1.80--2.15 (m, 6H), 2.36--2.43 (dd, *J* = 9.3, 13.2 Hz, 1H), 3.40--3.45 (m, 1H), 3.96 (s, 3H), 4.27 (br s, 1H), 4.42 (s, 1H), 6.61 (s, 1H), 6.91 (dd, *J* = 0.7, 7.6 Hz 1H), 7.95 (dt, *J* = 0.8, 2.4, 8.8 Hz, 1H), 8.06 (dd, *J* = 1.9, 8.8 Hz, 1H), 8.14 (d, *J* = 1.9 Hz, 1H), 8.41 (br s, 1H); ^13^C NMR (methanol-*d*~4~) δ 26.9, 29.0, 37.7, 43.4, 54.3, 60.2, 64.1, 111.7, 124.2, 136.2, 137.4, 140.6, 140.8, 145.8, 148.0, 159.1, 162.3, 165.8, 171.3; MS (ESI) *m*/*z* 300.5 \[(M -- fumaric)^+^, M = C~17~H~18~FN~3~O·0.5C~4~H~4~O~4~\]. Anal. (C~19~H~20~FN~3~O~3~·0.25 H~2~O) C, H, N.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(pyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**11a**) {#sec3.13}
------------------------------------------------------------------------------------------------------------------

A solution of compound **9** (322 mg, 0.87 mmol, 1.0 equiv), pyridine-3-boronic acid (140 mg, 1.14 mmol, 1.3 equiv), Pd(PPh~3~)~4~ (50 mg, 0.044 mmol, 5 mol %), and K~2~CO~3~ (242 mg, 1.75 mmol, 2.0 equiv) in toluene (10 mL), EtOH (2 mL), and water (2 mL) was degassed through bubbling nitrogen for 20 min. The mixture was sealed and heated over a sand bath at 110 °C for 22 h. After cooling to room temperature, 20 mL of H~2~O was added, and the organic product was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using *i*-PrOH--hexanes as the eluent to provide 263 mg (82%) of **11a**. ^1^H NMR (300 MHz, CDCl~3~) δ 1.41 (br s, 9H), 1.48--1.61 (m, 2H), 1.75--1.86 (m, 3H), 1.96--2.04 (m, 1H), 2.79--2.83 (dd, *J* = 3.8, 5.0 Hz, 1H), 4.16 (s, 1H), 4.35 (br s, 1H), 4.66 (s, 2 NH), 7.34 (d, *J* = 2.5 Hz, 1H), 7.38 (d, *J* = 4.9 Hz, 1H), 7.80 (dt, *J* = 7.9, 1.9 Hz, 1H), 7.96 (d, *J* = 2.2 Hz, 1H), 8.59 (dd, *J* = 4.9, 1.6 Hz, 1H), 8.69 (d, *J* = 1.8 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.3 (3 C), 28.8, 29.7, 40.3, 44.9, 55.9, 62.2, 79.5, 118.0, 123.6, 132.1, 134.1, 136.2, 136.9, 146.6, 148.9, 149.7, 154.5, 154.9; MS (ESI) *m*/*z* 367.6 (M + H)^+^.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(6-fluoropyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**11b**) {#sec3.14}
--------------------------------------------------------------------------------------------------------------------------

A solution of compound **9** (241 mg, 0.65 mmol, 1.0 equiv), 5-fluoropyridine-4-boronic acid (148 mg, 1.05 mmol, 1.6 equiv), Pd(OAc)~2~ (15 mg, 0.065 mmol, 10 mol %), P(*o-*tolyl)~3~ (40 mg, 0.131 mmol, 20 mol %), and Na~2~CO~3~ (139 mg, 1.31 mmol, 2.0 equiv) in DME (8 mL) and water (0.9 mL) was degassed through bubbling nitrogen for 20 min. The mixture was sealed and heated over a sand bath at 80 °C for 5 h. After cooling to room temperature, the mixture was poured into a saturated aqueous solution of NaHCO~3~ (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using EtOAc--hexanes as the eluent to provide 250 mg (99%) of **11b**. ^1^H NMR (300 MHz, CDCl~3~) δ 1.39 (br s, 9H), 1.51--1.59 (m, 2H), 1.81--1.85 (m, 3H), 1.94--2.00 (m, 1H), 2.79--2.84 (m, 1H), 4.16 (s, 1H), 4.35 (br s, 1H), 4.70 (s, 2 NH), 7.02 (dd, *J* = 2.9, 8.4 Hz, 1H), 7.34 (d, *J* = 2.25 Hz, 1H), 7.91 (ddd, *J* = 2.5, 8.4, 16 Hz, 1H), 7.96 (d, *J* = 2.25 Hz, 1H), 8.28 (d, *J* = 2.4 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.2 (3 C), 28.8, 29.7, 40.3, 44.8, 55.9, 62.1, 79.5, 109.5, 116.8, 132.0, 136.9, 141.5, 146.8, 147.5, 154.6, 154.9, 161.3, 164.5; MS (ESI) *m*/*z* 385.5 (M + H)^+^.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(6-chloropyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**11c**) {#sec3.15}
--------------------------------------------------------------------------------------------------------------------------

A solution of compound **9** (304 mg, 0.83 mmol, 1.0 equiv), 5-chloropyridine-4-boronic acid (208 mg, 1.32 mmol, 1.6 equiv), Pd(OAc)~2~ (19 mg, 0.083 mmol, 10 mol %), P(*o-*tolyl)~3~ (51 mg, 0.166 mmol, 20 mol %), and Na~2~CO~3~ (176 mg, 1.66 mmol, 2.0 equiv) in DME (6 mL) and water (0.7 mL) was degassed through bubbling nitrogen for 20 min. The mixture was sealed and heated over a sand bath at 80 °C for 5 h. After cooling to room temperature, the mixture was poured into a saturated aqueous solution of NaHCO~3~ (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using EtOAc--hexanes as the eluent to provide 305 mg (99%) of **11c** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.31 (br s, 9H), 1.43--1.50 (m, 2H), 1.72--1.76 (m, 3H), 1.85--1.92 (m, 1H), 2.70--2.74 (m, 1H), 4.06 (s, 1H), 4.26 (br s, 1H), 4.60 (s, 2 NH), 7.25 (d, *J* = 2.25 Hz, 1H), 7.30 (d, *J* = 8.2 Hz, 1H), 7.71 (dd, *J* = 2.5, 8.2 1H), 7.88 (d, *J* = 2.2 Hz, 1H), 8.38 (d, *J* = 2.2 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.3 (3 C), 28.8, 29.7, 40.3, 44.8, 55.9, 62.1, 79.5, 116.7, 124.2, 132.2, 133.1, 136.9, 139.0, 147.0, 149.5, 150.6, 154.4, 155.0; MS (ESI) *m*/*z* 401.5 (M + H)^+^.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(6-methoxypyridin-3-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**11d**) {#sec3.16}
---------------------------------------------------------------------------------------------------------------------------

A solution of **9** (337 mg, 0.92 mmol, 1.0 equiv), 2-methoxypyridine-5-boronic acid (182 mg, 1.2 mmol, 1.3 equiv), Pd(PPh~3~)~4~ (53 mg, 0.046 mmol, 5 mol %), and K~2~CO~3~ (253 mg, 1.83 mmol, 2.0 equiv) in toluene (12 mL), EtOH (2 mL), and H~2~O (2 mL) was placed in a resealable pressure vessel and degassed through bubbling nitrogen for 20 min. The vessel was sealed and placed on a sand bath that was heated at 110 °C overnight. After cooling to room temperature, H~2~O (20 mL) was added, and the organic product was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over anhydrous MgSO~4~, filtered through Celite, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using EtOAc--hexanes as the eluent to furnish compound **11d** (310 mg, 92%) as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.39 (br s, 9H), 1.50--1.59 (m, 2H), 1.76--1.88 (m, 3H), 1.91--1.98 (m, 1H), 2.77--2.81 (dd, *J* = 3.7, 5.0 Hz, 1H), 3.94 (s, 3H), 4.16 (s, 1H), 4.34 (br s, 1H), 4.78 (s, 2 NH), 6.79 (d, *J* = 8.5 Hz, 1H), 7.30 (d, *J* = 2.3 Hz, 1H), 7.65 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.93 (d, *J* = 2.3 Hz, 1H) 8.22 (d, *J* = 2.3 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.1 (3 C), 28.4, 28.6, 40.1, 44.8, 53.3, 55.3, 62.1, 79.3, 110.8, 118.1, 126.9, 128.4, 131.8, 136.7, 138.9, 145.8, 146.6, 154.8, 163.5; MS (ESI) *m*/*z* 397.5 (M + H)^+^.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(pyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**12a**) {#sec3.17}
------------------------------------------------------------------------------------------------------------------

A solution of compound **9** (354 mg, 0 0.96 mmol, 1.0 equiv), pyridine-4-boronic acid (154 mg, 1.25 mmol, 1.3 equiv), Pd(PPh~3~)~4~ (56 mg, 0.048 mmol, 5 mol %), and K~2~CO~3~ (266 mg, 1.92 mmol, 2.0 equiv) in toluene (10 mL), EtOH (2 mL), and water (2 mL) was degassed through bubbling nitrogen for 20 min. The mixture was sealed and heated over a sand bath at 110 °C for 22 h. After cooling to room temperature, 20 mL of H~2~O was added, and the organic product was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using *i*-PrOH--hexanes as the eluent to provide 340 mg (97%) of **12a**. ^1^H NMR (300 MHz, CDCl~3~) δ 1.39 (br s, 9H), 1.44--1.59 (m, 2H), 1.81--1.84 (m, 3H), 1.93--2.00 (m, 1H), 2.79--2.84 (dd, *J* = 3.8, 5.0 Hz, 1H), 4.16 (s, 1H), 4.36 (br s, 1H), 4.67 (s, 2 NH), 7.39--7.43 (m, 3H), 7.99 (d, *J* = 2.3 Hz, 1H), 8.66 (dd, *J* = 6.0, 1.5 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.3 (3 C), 28.8, 29.7, 40.4, 44.8, 55.8, 62.1, 79.5, 118.7, 123.4 (2 C), 132.2, 136.5, 146.4, 147.2, 150.5 (2 C), 153.9, 154.9; MS (ESI) *m*/*z* 367.6 (M + H)^+^.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(2-fluoropyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**12b**) {#sec3.18}
--------------------------------------------------------------------------------------------------------------------------

A solution of compound **9** (319 mg, 0.87 mmol, 1.0 equiv), 2-fluoropyridine-4-boronic acid (196 mg, 1.39 mmol, 1.6 equiv), Pd(OAc)~2~ (20 mg, 0.087 mmol, 10 mol %), P(*o-*tolyl)~3~ (53 mg, 0.173 mmol, 20 mol %), and Na~2~CO~3~ (184 mg, 1.73 mmol, 2.0 equiv) in DME (6 mL) and water (0.7 mL) was degassed through bubbling nitrogen for 20 min. The mixture was sealed and heated over a sand bath at 80 °C for 5 h. After cooling to room temperature, the mixture was poured into a saturated aqueous solution of NaHCO~3~ (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using EtOAc--hexanes as the eluent to provide 300 mg (92%) of **12b** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.4 (br s, 9H), 1.52--1.59 (m, 2H), 1.82--1.84 (m, 3H), 1.94--1.98 (m, 1H), 2.79--2.84 (m, 1H), 4.16 (s, 1H), 4.36 (br s, 1H), 4.77 (s, 2 NH), 7.06 (s, 1H), 7.34 (ddd, *J* = 1.6, 5.13, 8.4 Hz, 1H), 7.41 (d, *J* = 2.3 Hz, 1H), 8.0 (d, *J* = 2.3 Hz, 1H), 8.26 (d, *J* = 5.16 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.3 (3 C), 28.8, 29.7, 40.5, 44.8, 55.9, 62.1, 79.7, 108.8, 121.1, 132.5, 136.5, 147.8, 148.3, 152.0, 153.7, 155.0, 162.8, 166.0. MS (ESI) *m*/*z* 385.3 (M + H)^+^.

7-*tert*-Butoxycarbonyl-2-*exo-*\[2′-amino-3′-(2-chloropyridin-4-yl)-5′-pyridinyl\]-7-azabicyclo\[2.2.1\]heptane (**12c**) {#sec3.19}
--------------------------------------------------------------------------------------------------------------------------

A solution of compound **9** (192 mg, 0.52 mmol, 1.0 equiv), 2-chloropyridine-4-boronic acid (131 mg, 0.83 mmol, 1.6 equiv), Pd(OAc)~2~ (12 mg, 0.052 mmol, 10 mol %), P(*o-*tolyl)~3~ (32 mg, 0.104 mmol, 20 mol %), and Na~2~CO~3~ (111 mg, 1.04 mmol, 2.0 equiv) in DME (6 mL) and water (0.7 mL) was degassed through bubbling nitrogen for 20 min. The mixture was sealed and heated over a sand bath at 80 °C for 5 h. After cooling to room temperature, the mixture was poured into a saturated aqueous solution of NaHCO~3~ (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO~4~, filtered through Celite, and concentrated in vacuo. The resultant residue was purified by flash chromatography on silica gel using EtOAc--hexanes as the eluent to provide 112 mg (54%) of **12c** as a colorless oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.41 (br s, 9H), 1.49--1.61 (m, 2H), 1.77--1.83 (m, 3H), 1.94--2.00 (m, 1H), 2.78--2.83 (m, 1H), 4.16 (s, 1H), 4.36 (br s, 1H), 4.54 (s, 2 NH), 7.37 (dd, *J* = 1.4, 5.13 Hz, 1H), 7.40 (d, *J* = 2.22 Hz, 1H), 7.45 (s, 1H), 8.0 (d, *J* = 2.22 Hz, 1H), 8.44 (d, *J* = 5.10 Hz, 1H); ^13^C NMR (CDCl~3~) δ 28.3 (3 C), 28.8, 29.7, 40.5, 44.8, 55.9, 62.1, 79.6, 117.4, 122.0, 123.8, 132.4, 136.5, 147.8, 149.6, 150.2, 152.4, 153.8, 154.9; MS (ESI) *m*/*z* 401.3 (M + H)^+^.

Preparation of 2-Methoxypyidine-4-boronic Acid Pinacol Ester (**15**) {#sec3.20}
---------------------------------------------------------------------

A solution of 4-bromo-2-methoxypyridine (**14**) (462 mg, 2.46 mmol, 1.0 equiv), bis(pinacolato)diboron (749 mg, 2.95 mmol, 1.2 equiv), PdCl~2~(dppf) (54 mg, 0.074 mmol, 3 mol %), and KOAc (724 mg, 7.37 mmol, 3.0 equiv) in DMF (6 mL) in a resealable pressure vessel was degassed through bubbling nitrogen for 20 min. The reaction mixture was sealed and heated over a sand bath at 85 °C overnight. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through a plug of Celite and anhydrous Na~2~SO~4~. The solvent was removed in vacuo, and the residue was purified by flash chromatography on silica gel using EtOAc--MeOH as the eluent to provide 427.4 mg (74%) of **15** as a brownish oil. ^1^H NMR (300 MHz, CDCl~3~) δ 1.34 (s, 12H), 3.93 (s, 3H), 7.13 (s, 1H), 7.18 (d, *J* = 5.0 Hz, 1H), 8.18 (d, *J* = 5.0 Hz, 1H).

\[^3^H\]Epibatidine Binding Assay {#sec3.22}
---------------------------------

The inhibition of \[^3^H\]epibatidine binding at rat brain α4β2\*-nAChRs was conducted as previously reported.^[@ref21]^

Electrophysiology {#sec3.23}
-----------------

The electrophysiology assays with rat α4β2-, α3β4, and α7-nAChRs were conducted as previously described.^[@ref24]^

In Vivo Test {#sec3.24}
------------

The antinociception (tail-flick and hot-plate), locomotor, and body temperature tests were all conducted in mice as previously described.^[@ref21]^

Elemental analysis data. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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NRT

:   nicotine replacement therapy

CDC

:   Centers for Disease Control

nAChR

:   nicotinic acetylcholine receptor

ICSS

:   intracranial self-stimulation

CPP

:   conditioned place preference

DD

:   drug discrimination

SA

:   self-administration

PdCl~2~(dppf)

:   1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride

MCPBA

:   *meta*-chloroperoxybenzoic acid

MPE

:   maximum potential effect

DHβE

:   dihydro-β-erythroidine

AD~50~

:   the antagonist dose that blocks 50% of the nicotine response
